StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3029% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

ADMA Biologics's price to book ratio was 7.3× on Nov 11, 2026, against 10.6× a year earlier. Over the last 5 years it ranged from 1.9× to 24.7×, with a median of 6.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.3×−2.8
2025Dec 31, 202510.1×−7.4
2024Dec 31, 202417.5×+10.7
2023Dec 29, 20236.7×−0.9
2022Dec 30, 20227.6×+5.7
2021Dec 31, 20211.9×−0.6
2020Dec 31, 20202.4×−4.1
2019Dec 31, 20196.6×+3.6
2018Dec 31, 20183.0×−1.3
2017Dec 29, 20174.3×−14.1
2016Oct 31, 201618.4×+0.8
2015Dec 31, 201517.6×+6.4
2014Dec 31, 201411.2×−17.0
2013Oct 31, 201328.2×–

More ADMA Biologics figures

See a number that looks wrong?